Gene Dose of Apolipoprotein E Type 4 Allele and the Risk of Alzheimer's Disease in Late Onset Families
The DOI matches its Crossref record; 17 of the 17 references it cites were found in a registry or an index.
Abstract
The apolipoprotein E type 4 allele ( APOE -ε4) is genetically associated with the common late onset familial and sporadic forms of Alzheimer's disease (AD). Risk for AD increased from 20% to 90% and mean age at onset decreased from 84 to 68 years with increasing number of APOE -ε4 alleles in 42 families with late onset AD. Thus APOE -ε4 gene dose is a major risk factor for late onset AD and, in these families, homozygosity for APOE -ε4 was virtually sufficient to cause AD by age 80.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The check wasn’t confident either way, so it gives no verdict — never disputed.
In the citing paper
“Common variants of the apolipoprotein E gene (APOE) influence the risk of Alzheimer’s disease: APOE4 is linked to high risk, APOE3 is considered to confer a neutral risk, and APOE2 is associated with relative protection.2–5”
From APOE3 Christchurch Heterozygosity and Autosomal Dominant Alzheimer’s Disease (2024) · cites this paper as [3]
Experimental — accuracy not yet measuredIn the citing paper
“Compared to the most common APOE3/3 genotype, each additional copy of the APOE4 allele is associated with a higher risk of Alzheimer’s dementia and a younger mean age at dementia onset, such that APOE4 homozygotes are at the highest risk”
From Exceptionally low likelihood of Alzheimer’s dementia in APOE2 homozygotes from a 5,000-person neuropathological study (2020) · cites this paper as [3]
In the citing paper
“while the presence of one or two copies of the APOE2 allele is associated with a lower risk of Alzheimer’s dementia and an older mean age at dementia onset1–4.”
From Exceptionally low likelihood of Alzheimer’s dementia in APOE2 homozygotes from a 5,000-person neuropathological study (2020) · cites this paper as [3]
In the citing paper
“such that APOE4 homozygotes are at the highest risk”
From Exceptionally low likelihood of Alzheimer’s dementia in APOE2 homozygotes from a 5,000-person neuropathological study (2020) · cites this paper as [3]
In the citing paper
“Apolipoprotein E (APOE), the major susceptibility gene for late-onset Alzheimer’s disease (AD), has three common alleles (APOE2, 3, and 4), giving rise to six genotypes (APOE2/2, 2/3, 3/3, 2/4, 3/4, and 4/4).”
From Exceptionally low likelihood of Alzheimer’s dementia in APOE2 homozygotes from a 5,000-person neuropathological study (2020) · cites this paper as [3]
91 more claims about this paper
Create a free account to see every claim other papers make about this one.
Citations
Cites
Cox, D. R., & Oakes, D. (2018) · Chapman & Hall/CRC eBooks · doi:10.1201/9781315137438 · Cited by 6,234
Goate, A., Chartier-Harlin, M.-C., Mullan, M., Brown, J., Crawford, F., Fidani, L., Giuffra, L., Haynes, A., Irving, N., James, L., et al. (1991) · Nature · doi:10.1038/349704a0 · Cited by 4,659
Self-citationStrittmatter, W. J., Saunders, A. M., Schmechel, D., Pericak-Vance, M., Enghild, J., Salvesen, G. S., & Roses, A. D. (1993) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.90.5.1977 · Cited by 4,268
Self-citationAssociation of apolipoprotein E allele ϵ4 with late‐onset familial and sporadic Alzheimer's disease
Saunders, A. M., Strittmatter, W. J., Schmechel, D., St. George-Hyslop, P. H., Pericak-Vance, M. A., Joo, S. H., Rosi, B. L., Gusella, J. F., Crapper-MacLachlan, D. R., Alberts, M. J., et al. (1993) · Neurology · doi:10.1212/wnl.43.8.1467 · Cited by 3,786
Self-citationMiller, R. G. (1981) · Cited by 3,336
Regression analysis of multivariate incomplete failure time data by modeling marginal distributions
Wei, L. J., Lin, D. Y., & Weissfeld, L. (1989) · Journal of the American Statistical Association · doi:10.1080/01621459.1989.10478873 · Cited by 1,868
Schmechel, D. E., Saunders, A. M., Strittmatter, W. J., Crain, B. J., Hulette, C. M., Joo, S. H., Pericak-Vance, M. A., Goldgaber, D., & Roses, A. D. (1993) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.90.20.9649 · Cited by 1,525
Self-citationThe Genetic Defect Causing Familial Alzheimer's Disease Maps on Chromosome 21
St George-Hyslop, P. H., Tanzi, R. E., Polinsky, R. J., Haines, J. L., Nee, L., Watkins, P. C., Myers, R. H., Feldman, R. G., Pollen, D., Drachman, D., et al. (1987) · Science · doi:10.1126/science.2880399 · Cited by 1,163
Self-citationNamba, Y., Tomonaga, M., Kawasaki, H., Otomo, E., & Ikeda, K. (1991) · Brain Research · doi:10.1016/0006-8993(91)91092-f · Cited by 1,157
Genetic Linkage Evidence for a Familial Alzheimer's Disease Locus on Chromosome 14
Schellenberg, G. D., Bird, T. D., Wijsman, E. M., Orr, H. T., Anderson, L., Nemens, E., White, J. A., Bonnycastle, L., Weber, J. L., Alonso, M. E., et al. (1992) · Science · doi:10.1126/science.1411576 · Cited by 946
Research works printed but not linked: 3
- SAS/STAT User's Guide Release 6.03 Edition (1988).
- SAS User's Guide: Statistics Version 5 Edition (1985).
- 10.1073/pnas.90.5.1977 · DOI · Paper page
Cited by
Items 501–600 of 1,689
Deelen, J., Beekman, M., Uh, H., Helmer, Q., Kuningas, M., Christiansen, L., Kremer, D., van der Breggen, R., Suchiman, H. E. D., Lakenberg, N., et al. (2011) · Aging Cell · doi:10.1111/j.1474-9726.2011.00705.x · Cited by 285
“Like low IGF-1 levels, ApoE e4 was previously associated with an increased risk of developing cardiovascular disease and neurodegenerative disease (Corder et al., 1993; Eichner et al., 1993; Christensen et al., 2006).”
A polymorphism in the regulatory region of APOE associated with risk for Alzheimer's dementia
Bullido, M. J., Artiga, M. J., Recuero, M., Sastre, I., García, M. A., Aldudo, J., Lendon, C., Han, S. W., Morris, J. C., Frank, A., et al. (1998) · Nature Genetics · doi:10.1038/ng0198-69 · Cited by 286
Apolipoprotein E in lipid metabolism and neurodegenerative disease
Yang, L. G., March, Z. M., Stephenson, R. A., & Narayan, P. S. (2023) · Trends in Endocrinology & Metabolism · doi:10.1016/j.tem.2023.05.002 · Cited by 286
“LOAD risk increases with APOE4 gene dose [26,27].”
The genetic architecture of Alzheimer's disease: beyond APP, PSENs and APOE
Guerreiro, R. J., Gustafson, D. R., & Hardy, J. (2012) · Neurobiology of Aging · doi:10.1016/j.neurobiolaging.2010.03.025 · Cited by 285
“APOE is known to act in a dose dependent manner in AD: the effect of the 4 allele in the risk for AD increases from 20% to 90% and the mean age of onset decreases from 84 to 68 years with the increase in the number of 4 alleles (Corder et al., 1993).”
Identification of a Novel Common Genetic Risk Factor for Lumbar Disk Disease
Paassilta, P. (2001) · JAMA · doi:10.1001/jama.285.14.1843 · Cited by 289
Hamilton, L. K., Dufresne, M., Joppé, S. E., Petryszyn, S., Aumont, A., Calon, F., Barnabé-Heider, F., Furtos, A., Parent, M., Chaurand, P., et al. (2015) · Cell Stem Cell · doi:10.1016/j.stem.2015.08.001 · Cited by 284
Disease-modifying therapies for Alzheimer disease: Challenges to early intervention
Cummings, J. L., Doody, R., & Clark, C. (2007) · Neurology · doi:10.1212/01.wnl.0000295996.54210.69 · Cited by 279
Kilian, J., & Kitazawa, M. (2018) · Biomedical Journal · doi:10.1016/j.bj.2018.06.001 · Cited by 265
“[4] Corder EH, Saunders AM, Strittmatter WJ, Schmechel DE, Gaskell PC, Small GW, et al.”
BackgroundCyclobutanes in Small‐Molecule Drug Candidates
van der Kolk, M. R., Janssen, M. A. C. H., Rutjes, F. P. J. T., & Blanco‐Ania, D. (2022) · ChemMedChem · doi:10.1002/cmdc.202200020 · Cited by 274
Deciphering the astrocyte reaction in Alzheimer's disease
Perez-Nievas, B. G., & Serrano-Pozo, A. (2018) · Frontiers in Aging Neuroscience · doi:10.3389/fnagi.2018.00114 · Cited by 282
“Moreover, the ε4 allele anticipates the onset of AD in a dose-dependent manner (Corder et al., 1993).”
BackgroundMolecular genetics of Alzheimer’s disease
St George-Hyslop, P. H. (2000) · Biological Psychiatry · doi:10.1016/s0006-3223(99)00301-7 · Cited by 265
Kanekiyo, T., & Bu, G. (2014) · Frontiers in Aging Neuroscience · doi:10.3389/fnagi.2014.00093 · Cited by 281
“(2010). Low-density lipoprotein receptor-related protein 1 (LRP1) mediates neuronal Aβ42 uptake and lysosomal trafficking. PLoS ONE 5:e11884. doi: 10.1371/journal.pone.0011884 Fujiyoshi, M., Tachikawa, M., Ohtsuki, S., Ito, S., Uchida, Y., Akanuma, S., et al. (2011). Amyloid-β peptide(1-40) elimination from cerebrospi…”
InfluentialLipid droplets in the nervous system
Ralhan, I., Chang, C.-L., Lippincott-Schwartz, J., & Ioannou, M. S. (2021) · Journal of Cell Biology · doi:10.1083/jcb.202102136 · Cited by 281
“The ApoE4 allele has the highest risk for developing the disease (Corder et al., 1993; Strittmatter et al., 1993), while the E2 and E3 alleles are neuroprotective (Corder et al.”
BackgroundKimura, R., Kamino, K., Yamamoto, M., Nuripa, A., Kida, T., Kazui, H., Hashimoto, R., Tanaka, T., Kudo, T., Yamagata, H., et al. (2007) · Human Molecular Genetics · doi:10.1093/hmg/ddl437 · Cited by 281
Circle of Willis Atherosclerosis Is a Risk Factor for Sporadic Alzheimer’s Disease
Roher, A. E., Esh, C., Kokjohn, T. A., Kalback, W., Luehrs, D. C., Seward, J. D., Sue, L. I., & Beach, T. G. (2003) · Arteriosclerosis, Thrombosis, and Vascular Biology · doi:10.1161/01.atv.0000095973.42032.44 · Cited by 280
Apolipoprotein E allele ∈4, dementia, and cognitive decline in a population sample
Henderson, A. S., Jorm, A. F., Korten, A. E., Christensen, H., Jacomb, P. A., Easteal, S., Croft, L., & Mackinnon, A. J. (1995) · The Lancet · doi:10.1016/s0140-6736(95)92405-1 · Cited by 272
Fernández-Calle, R., Konings, S. C., Frontiñán-Rubio, J., García-Revilla, J., Camprubí-Ferrer, L., Svensson, M., Martinson, I., Boza-Serrano, A., Venero, J. L., Nielsen, H. M., et al. (2022) · Molecular Neurodegeneration · doi:10.1186/s13024-022-00566-4 · Cited by 278
Reviews: Current Concepts in Alzheimer's Disease: A Multidisciplinary Review
Minati, L., Edginton, T., Grazia Bruzzone, M., & Giaccone, G. (2009) · American Journal of Alzheimer's Disease & Other Dementias® · doi:10.1177/1533317508328602 · Cited by 268
“Patients with AD are more likely to carry the e4 allele than the general population, and a proportional relationship between gene dose and risk and age of onset has been found.(11) Conversely, the e2 allele may confer a relative protection.”
BackgroundAnalysis of European mitochondrial haplogroups with Alzheimer disease risk
van der Walt, J. M., Dementieva, Y. A., Martin, E. R., Scott, W. K., Nicodemus, K. K., Kroner, C. C., Welsh-Bohmer, K. A., Saunders, A. M., Roses, A. D., Small, G. W., et al. (2004) · Neuroscience Letters · doi:10.1016/j.neulet.2004.04.051 · Cited by 280
“Because the APOE4 allele is associated with a known higher risk of AD[5], we assessed both interaction and confounding effects between APOE4 carrier status and mitochondrial haplogroups and SNPs using logistic regression models.”
MethodSelf-citationVoxelwise genome-wide association study (vGWAS)
Stein, J. L., Hua, X., Lee, S., Ho, A. J., Leow, A. D., Toga, A. W., Saykin, A. J., Shen, L., Foroud, T., Pankratz, N., et al. (2010) · NeuroImage · doi:10.1016/j.neuroimage.2010.02.032 · Cited by 270
Cummings, J. (2023) · Drugs · doi:10.1007/s40265-023-01858-9 · Cited by 241
“The apolipoprotein E ε4 (APOE4) gene increases the risk of AD and decreases the age of onset [33, 34].”
BackgroundAre schizophrenic and bipolar disorders related? A review of family and molecular studies
Berrettini, W. H. (2000) · Biological Psychiatry · doi:10.1016/s0006-3223(00)00883-0 · Cited by 267
“[Davies et al 1994]; the other is apolipoprotein E in late onset Alzheimer’s disease (Corder et al 1993; Mayeux et al 1993; Tsai et al 1994).”
BackgroundFernandez, C. G., Hamby, M. E., McReynolds, M. L., & Ray, W. J. (2019) · Frontiers in Aging Neuroscience · doi:10.3389/fnagi.2019.00014 · Cited by 277
Childhood mental ability and dementia
Whalley, L. J., Starr, J. M., Athawes, R., Hunter, D., Pattie, A., & Deary, I. J. (2000) · Neurology · doi:10.1212/wnl.55.10.1455 · Cited by 274
“It comprised a variety of item types as follows: following direction (14 items), same-opposites (11), word classification (10), analogies (8), practical items (6), reasoning (5), proverbs (4), arithmetic (4), spatial items (4), mixed sentences (3), cipher decoding (2), and other items (4).”
BackgroundNathan, B. P., Chang, K.-C., Bellosta, S., Brisch, E., Ge, N., Mahley, R. W., & Pitas, R. E. (1995) · Journal of Biological Chemistry · doi:10.1074/jbc.270.34.19791 · Cited by 276
Atypical aging in down syndrome
Zigman, W. B. (2013) · Developmental Disabilities Research Reviews · doi:10.1002/ddrr.1128 · Cited by 260
Ye, S., Huang, Y., Müllendorff, K., Dong, L., Giedt, G., Meng, E. C., Cohen, F. E., Kuntz, I. D., Weisgraber, K. H., & Mahley, R. W. (2005) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0508693102 · Cited by 275
Nishitsuji, K., Hosono, T., Nakamura, T., Bu, G., & Michikawa, M. (2011) · Journal of Biological Chemistry · doi:10.1074/jbc.m111.225532 · Cited by 275
Antisense oligonucleotides: translation from mouse models to human neurodegenerative diseases
Schoch, K. M., & Miller, T. M. (2017) · Neuron · doi:10.1016/j.neuron.2017.04.010 · Cited by 274
“It is well established that the apolipoprotein isoform ApoE-ε4 confers a 2- to 12-fold risk for developing AD in humans, depending on the number of ε4 alleles (Corder et al., 1993).”
Nyberg, L., & Pudas, S. (2019) · Annual Review of Psychology · doi:10.1146/annurev-psych-010418-103052 · Cited by 248
Statement on Use of Apolipoprotein E Testing for Alzheimer Disease
Farrer, L. A. (1995) · JAMA: The Journal of the American Medical Association · doi:10.1001/jama.1995.03530200063039 · Cited by 244
Exploring the Etiology of Alzheimer Disease Using Molecular Genetics
Lendon, C. L. (1997) · JAMA: The Journal of the American Medical Association · doi:10.1001/jama.1997.03540340059034 · Cited by 273
TOKUDA, T., CALERO, M., MATSUBARA, E., VIDAL, R., KUMAR, A., PERMANNE, B., ZLOKOVIC, B., SMITH, J. D., LADU, M. J., ROSTAGNO, A., et al. (2000) · Biochemical Journal · doi:10.1042/bj3480359 · Cited by 272
Lim, A. S. P., Yu, L., Kowgier, M., Schneider, J. A., Buchman, A. S., & Bennett, D. A. (2013) · JAMA Neurology · doi:10.1001/jamaneurol.2013.4215 · Cited by 261
Apolipoprotein E: risk factor for Alzheimer disease.
Tsai, M. S., Tangalos, E. G., Petersen, R. C., Smith, G. E., Schaid, D. J., Kokmen, E., Ivnik, R. J., & Thibodeau, S. N. (1994) · PubMed · Cited by 310
Mild cognitive impairment: pathology and mechanisms
Mufson, E. J., Binder, L., Counts, S. E., DeKosky, S. T., deToledo-Morrell, L., Ginsberg, S. D., Ikonomovic, M. D., Perez, S. E., & Scheff, S. W. (2012) · Acta Neuropathologica · doi:10.1007/s00401-011-0884-1 · Cited by 257
“The seminal findings of Roses and colleagues revealed that apolipoprotein E (APOE) e4 carriers are at increased risk for AD [32].”
Markowicz-Piasecka, M., Sikora, J., Szydłowska, A., Skupień, A., Mikiciuk-Olasik, E., & Huttunen, K. M. (2017) · Pharmaceutical Research · doi:10.1007/s11095-017-2199-y · Cited by 257
“uptake of lipoprotein, is coded by a gene which has three polymorphic alleles: ε2, ε3 and ε4 (34).”
BackgroundProteomic landscape of Alzheimer’s Disease: novel insights into pathogenesis and biomarker discovery
Bai, B., Vanderwall, D., Li, Y., Wang, X., Poudel, S., Wang, H., Dey, K. K., Chen, P.-C., Yang, K., & Peng, J. (2021) · Molecular Neurodegeneration · doi:10.1186/s13024-021-00474-z · Cited by 257
De Ferrari, G. V., Papassotiropoulos, A., Biechele, T., Wavrant De-Vrieze, F., Avila, M. E., Major, M. B., Myers, A., Sáez, K., Henríquez, J. P., Zhao, A., et al. (2007) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0603523104 · Cited by 270
Interface between tauopathies and synucleinopathies: A tale of two proteins
Galpern, W. R., & Lang, A. E. (2006) · Annals of Neurology · doi:10.1002/ana.20819 · Cited by 263
Head (2012) · doi:10.1001/archneurol.2011.845 · Cited by 267
“T HE PRESENCE OF AN APOE ε4 allele is the most established genetic risk factor for Alzheimer disease (AD), with a higher percentage of individuals with AD having an ε4 allele in comparison with the general population.(1,2) In addition, the age at dementia onset is earlier,(2,3) and the rate of cognitive decline may be…”
BackgroundAbildayeva, K., Jansen, P. J., Hirsch-Reinshagen, V., Bloks, V. W., Bakker, A. H. F., Ramaekers, F. C. S., de Vente, J., Groen, A. K., Wellington, Kuipers, F., et al. (2006) · Journal of Biological Chemistry · doi:10.1074/jbc.m601019200 · Cited by 267
Fibrillogenesis in Alzheimer's disease of amyloid β peptides and apolipoprotein E
Castano, E. M., Prelli, F., Wisniewski, T., Golabek, A., Kumar, R. A., Soto, C., & Frangione, B. (1995) · Biochemical Journal · doi:10.1042/bj3060599 · Cited by 267
Neuroimaging endophenotypes: Strategies for finding genes influencing brain structure and function
Glahn, D. C., Thompson, P. M., & Blangero, J. (2007) · Human Brain Mapping · doi:10.1002/hbm.20401 · Cited by 264
“Sixteen of these subjects had at least one copy of the apolipoprotein (APOE) e4 allele, a gene strongly linked to Alzheimer’s dementia [Corder et al., 1993; Saunders et al., 1993].”
BackgroundTherapies for Prevention and Treatment of Alzheimer’s Disease
Mendiola-Precoma, J., Berumen, L. C., Padilla, K., & Garcia-Alcocer, G. (2016) · BioMed Research International · doi:10.1155/2016/2589276 · Cited by 241
“Review Article Therapies for Prevention and Treatment of Alzheimer’s Disease J. Mendiola-Precoma, L. C. Berumen, K. Padilla, and G. Garcia-Alcocer Laboratorio de Investigación Genética, Facultad de Quı́mica, Universidad Autónoma de Querétaro, Cerro de las Campanas S/N, Centro Universitario, 76010 Santiago de Quere…”
MethodInfluentialHippocampal volumes in cognitively normal persons at genetic risk for Alzheimer's disease
Reiman, E. M., Uecker, A., Caselli, R. J., Lewis, S., Bandy, D., De Leon, M. J., De Santi, S., Convit, A., Osborne, D., Weaver, A., et al. (1998) · Annals of Neurology · doi:10.1002/ana.410440226 · Cited by 266
Alzheimer's disease, a multifactorial disorder seeking multitherapies
Iqbal, K., & Grundke‐Iqbal, I. (2010) · Alzheimer's & Dementia · doi:10.1016/j.jalz.2010.04.006 · Cited by 255
“In the sporadic AD, the presence of one or two alleles of apolipoprotein (APOE) 34 as opposed to APOE 32 or APOE 33 increases the disease risk by several folds [11].”
BackgroundDean, D. C., Jerskey, B. A., Chen, K., Protas, H., Thiyyagura, P., Roontiva, A., O'Muircheartaigh, J., Dirks, H., Waskiewicz, N., Lehman, K., et al. (2014) · JAMA Neurology · doi:10.1001/jamaneurol.2013.4544 · Cited by 263
Shih, R. A., Hu, H., Weisskopf, M. G., & Schwartz, B. S. (2007) · Environmental Health Perspectives · doi:10.1289/ehp.9786 · Cited by 263
“The APOE ε4 allele is a risk factor for late-onset Alzheimier disease (Corder et al. 1993; Meyer et al. 1998; Saunders et al. 1993), hippocampal atrophy (Moffat et al. 2000), and senile plaques (Zubenko et al. 1994).”
BackgroundSnyder, H. M., Asthana, S., Bain, L., Brinton, R., Craft, S., Dubal, D. B., Espeland, M. A., Gatz, M., Mielke, M. M., Raber, J., et al. (2016) · Alzheimer's & Dementia · doi:10.1016/j.jalz.2016.08.004 · Cited by 262
“[34] Corder EH, Saunders AM, Strittmatter WJ, Schmechel DE,”
BackgroundResults of a high-resolution genome screen of 437 Alzheimer's Disease families
Blacker, D. (2003) · Human Molecular Genetics · doi:10.1093/hmg/ddg007 · Cited by 262
High Density Lipoprotein Structure–Function and Role in Reverse Cholesterol Transport
Lund-Katz, S., & Phillips, M. C. (2010) · Subcellular Biochemistry · doi:10.1007/978-90-481-8622-8_7 · Cited by 262
“The apoE4 allele is a major susceptibility gene that is associated with 40–65% of cases of sporadic and familial Alzheimer’s disease; individuals carrying this isoform have an increased occurrence and reduced age of onset of the disease (Corder et al., 1993).”
BackgroundSando, S. B., Melquist, S., Cannon, A., Hutton, M. L., Sletvold, O., Saltvedt, I., White, L. R., Lydersen, S., & Aasly, J. O. (2008) · BMC Neurology · doi:10.1186/1471-2377-8-9 · Cited by 261
“APOE ε4 acts in a dose-dependant manner: carriers of two APOE ε4 alleles have a higher risk and earlier onset of AD than heterozygous subjects [12-14].”
BackgroundGreenberg, S. M., Briggs, M. E., Hyman, B. T., Kokoris, G. J., Takis, C., Kanter, D. S., Kase, C. S., & Pessin, M. S. (1996) · Stroke · doi:10.1161/01.str.27.8.1333 · Cited by 259
The case described by Alois Alzheimer in 1911
Möller, H.-J., & Graeber, M. B. (1998) · European Archives of Psychiatry and Clinical Neuroscience · doi:10.1007/s004060050027 · Cited by 224
“From a molecular genetic point of view it is of interest to note that Alzheimer’s patient lacks the common Alzheimer’s disease susceptibility allele, apolipoprotein Ee4 ( Corder et al. 1993; Saunders et al. 1993).”
BackgroundThe role of APOE -ε4 in longitudinal cognitive decline: MacArthur Studies of Successful Aging
Bretsky, P., Guralnik, J. M., Launer, L., Albert, M., & Seeman, T. E. (2003) · Neurology · doi:10.1212/01.wnl.0000055875.26908.24 · Cited by 257
Genetic Exceptionalism in Medicine: Clarifying the Differences between Genetic and Nongenetic Tests
Green, M. J., & Botkin, J. R. (2003) · Annals of Internal Medicine · doi:10.7326/0003-4819-138-7-200304010-00013 · Cited by 257
“Genetic tests are currently used in a variety of ways: to confirm a suspected diagnosis, such as the fragile X syndrome in a developmentally delayed child (16, 17); for heterozygote carrier testing, such as in carriers of sickle cell trait (18); for prenatal or preimplantation diagnosis of diseases like Duchenne muscu…”
BackgroundGenome-wide Association Study Implicates a Chromosome 12 Risk Locus for Late-Onset Alzheimer Disease
Beecham, G. W., Martin, E. R., Li, Y.-J., Slifer, M. A., Gilbert, J. R., Haines, J. L., & Pericak-Vance, M. A. (2009) · The American Journal of Human Genetics · doi:10.1016/j.ajhg.2008.12.008 · Cited by 260
Self-citationThe genetics and neuropathology of Alzheimer’s disease
Schellenberg, G. D., & Montine, T. J. (2012) · Acta Neuropathologica · doi:10.1007/s00401-012-0996-2 · Cited by 242
“On a population level, people with an e4 allele have lower average onset age and those with an e2 allele have a higher average onset age for AD [21].”
Extracellular protein components of amyloid plaques and their roles in Alzheimer’s disease pathology
Rahman, M. M., & Lendel, C. (2021) · Molecular Neurodegeneration · doi:10.1186/s13024-021-00465-0 · Cited by 239
Hureau, C., & Faller, P. (2009) · Biochimie · doi:10.1016/j.biochi.2009.03.013 · Cited by 259
Role of Tissue Plasminogen Activator Receptor LRP in Hippocampal Long-Term Potentiation
Zhuo, M., Holtzman, D. M., Li, Y., Osaka, H., DeMaro, J., Jacquin, M., & Bu, G. (2000) · The Journal of Neuroscience · doi:10.1523/jneurosci.20-02-00542.2000 · Cited by 258
“First, LRP is the major neuronal receptor for apoE/lipoproteins (Bellosta et al., 1995; Holtzman et al., 1995; Fagan et al., 1996), and the e4 allele of apoE is a strong genetic risk factor for AD (Corder et al., 1993; Strittmatter et al., 1993).”
BackgroundShaw, P., Lerch, J. P., Pruessner, J. C., Taylor, K. N., Rose, A. B., Greenstein, D., Clasen, L., Evans, A., Rapoport, J. L., & Giedd, J. N. (2007) · The Lancet Neurology · doi:10.1016/s1474-4422(07)70106-0 · Cited by 257
Saleem, S., & Kannan, R. R. (2018) · Cell Death Discovery · doi:10.1038/s41420-018-0109-7 · Cited by 239
Pulver, A. E., Lasseter, V. K., Kasch, L., Wolyniec, P., Nestadt, G., Blouin, J., Kimberland, M., Babb, R., Vourlis, S., Chen, H., et al. (1995) · American Journal of Medical Genetics · doi:10.1002/ajmg.1320600316 · Cited by 255
Edmonds, E. C., Delano‐Wood, L., Clark, L. R., Jak, A. J., Nation, D. A., McDonald, C. R., Libon, D. J., Au, R., Galasko, D., Salmon, D. P., et al. (2015) · Alzheimer's & Dementia · doi:10.1016/j.jalz.2014.03.005 · Cited by 256
“Biological markers included cerebrospinal fluid (CSF) concentrations of hyperphosphorylated tau (p-tau 181p ), b -amyloid (A b 1-42 ), the ratio of p-tau 181p to A b 1-42 [15], and frequency of the apolipoprotein E ( APOE ) ε 4 allele [16–18].”
Modulation of Secreted β-Amyloid Precursor Protein and Amyloid β-Peptide in Brain by Cholesterol
Howland, D. S., Trusko, S. P., Savage, M. J., Reaume, A. G., Lang, D. M., Hirsch, J. D., Maeda, N., Siman, R., Greenberg, B. D., Scott, R. W., et al. (1998) · Journal of Biological Chemistry · doi:10.1074/jbc.273.26.16576 · Cited by 255
Apolipoprotein J (clusterin) and Alzheimer's disease
Calero, M., Rostagno, A., Matsubara, E., Zlokovic, B., Frangione, B., & Ghiso, J. (2000) · Microscopy Research and Technique · doi:10.1002/1097-0029(20000815)50:4<305::aid-jemt10>3.0.co;2-l · Cited by 256
APOE mediated neuroinflammation and neurodegeneration in Alzheimer’s disease
Parhizkar, S., & Holtzman, D. M. (2022) · Seminars in Immunology · doi:10.1016/j.smim.2022.101594 · Cited by 255
Anderson, D. H., Ozaki, S., Nealon, M., Neitz, J., Mullins, R. F., Hageman, G. S., & Johnson, L. V. (2001) · American Journal of Ophthalmology · doi:10.1016/s0002-9394(00)00961-2 · Cited by 255
Preliminary Report of a Genetic Basis for Cognitive Decline After Cardiac Operations
Tardiff, B. E., Newman, M. F., Saunders, A. M., Strittmatter, W. J., Blumenthal, J. A., White, W. D., Croughwell, N. D., Davis, R. D., Roses, A. D., & Reves, J. G. (1997) · The Annals of Thoracic Surgery · doi:10.1016/s0003-4975(97)00757-1 · Cited by 257
“We hypothesized that variant forms of the apolipoprotein E (APOE) gene that encodes the APOE protein responsible for repair of neuronal injury would make patients more susceptible to cognitive loss in the postoperative period [5, 6].”
BackgroundSelf-citationThe cause of neuronal degeneration in Alzheimer’s disease
Vickers, J. (2000) · Progress in Neurobiology · doi:10.1016/s0301-0082(99)00023-4 · Cited by 254
HDL and cholesterol handling in the brain
Vitali, C., Wellington, C. L., & Calabresi, L. (2014) · Cardiovascular Research · doi:10.1093/cvr/cvu148 · Cited by 254
“Inheritance of apoE4 increases AD risk and decreases AD age of onset in a gene-dose dependent manner, 24,29 and accounts for 25% of heritability.”
Cognitive Phenotypes in Alzheimer's Disease and Genetic Risk
Snowden, J. S., Stopford, C. L., Julien, C. L., Thompson, J. C., Davidson, Y., Gibbons, L., Pritchard, A., Lendon, C. L., Richardson, A. M., Varma, A., et al. (2007) · Cortex · doi:10.1016/s0010-9452(08)70683-x · Cited by 254
CORDER, E. H., GHEBREMEDHIN, E., TAYLOR, M. G., THAL, D. R., OHM, T. G., & BRAAK, H. (2004) · Annals of the New York Academy of Sciences · doi:10.1196/annals.1297.005 · Cited by 254
Self-citationOlfactory dysfunction in aging and neurodegenerative diseases
Dan, X., Wechter, N., Gray, S., Mohanty, J. G., Croteau, D. L., & Bohr, V. A. (2021) · Ageing Research Reviews · doi:10.1016/j.arr.2021.101416 · Cited by 219
Compartmentalization of β-secretase (Asp2) into low-buoyant density, noncaveolar lipid rafts
Riddell, D. R., Christie, G., Hussain, I., & Dingwall, C. (2001) · Current Biology · doi:10.1016/s0960-9822(01)00394-3 · Cited by 253
Payami, H., Zareparsi, S., Montee, K. R., Sexton, G. J., Kaye, J. A., Bird, T. D., Yu, C. E., Wijsman, E. M., Heston, L. L., Litt, M. J., et al. (1996) · PubMed Central · Cited by 293
Saunders, A., Hulette, C., Welsh-Bohmer, K., Schmechel, D., Crain, B., Burke, Jr., Alberts, M., Strittmatter, W., Breitner, J., Rosenberg, C., et al. (1996) · The Lancet · doi:10.1016/s0140-6736(96)01251-2 · Cited by 253
Self-citationNagy, Z. S., Esiri, M. M., Jobst, K. A., Johnston, C., Litchfield, S., Sim, E., & Smith, A. D. (1995) · Neuroscience · doi:10.1016/0306-4522(95)00331-c · Cited by 250
Association of Lifetime Intellectual Enrichment With Cognitive Decline in the Older Population
Vemuri, P., Lesnick, T. G., Przybelski, S. A., Machulda, M., Knopman, D. S., Mielke, M. M., Roberts, R. O., Geda, Y. E., Rocca, W. A., Petersen, R. C., et al. (2014) · JAMA Neurology · doi:10.1001/jamaneurol.2014.963 · Cited by 224
Apolipoprotein E4 and coronary heart disease in middle-aged men who smoke: a prospective study
Humphries, S. E., Talmud, P. J., Hawe, E., Bolla, M., Day, I. N., & Miller, G. J. (2001) · The Lancet · doi:10.1016/s0140-6736(01)05330-2 · Cited by 252
Evidence for impaired amyloid β clearance in Alzheimer's disease
Wildsmith, K. R., Holley, M., Savage, J. C., Skerrett, R., & Landreth, G. E. (2013) · Alzheimer's Research & Therapy · doi:10.1186/alzrt187 · Cited by 236
Tong, M., Neusner, A., Longato, L., Lawton, M., Wands, J. R., & de la Monte, S. M. (2009) · Journal of Alzheimer’s Disease · doi:10.3233/jad-2009-1115 · Cited by 249
Risk Factors for β-Amyloid Deposition in Healthy Aging: Vascular and Genetic Effects
Rodrigue, K. M., Rieck, J. R., Kennedy, K. M., Devous, M. D., Diaz-Arrastia, R., & Park, D. C. (2013) · JAMA Neurology · doi:10.1001/jamaneurol.2013.1342 · Cited by 249
Young, J., Modat, M., Cardoso, M. J., Mendelson, A., Cash, D., & Ourselin, S. (2013) · NeuroImage Clinical · doi:10.1016/j.nicl.2013.05.004 · Cited by 249
“The most common allele is APOE ε 3, but carriers of the APOE ε 4 variant are at heightened risk of AD, whereas the APOE ε 2 variant confers some protection on carriers (Corder et al., 1993, 1994).”
BackgroundHabchi, J., Chia, S., Galvagnion, C., Michaels, T. C. T., Bellaiche, M. M. J., Ruggeri, F. S., Sanguanini, M., Idini, I., Kumita, J. R., Sparr, E., et al. (2018) · Nature Chemistry · doi:10.1038/s41557-018-0031-x · Cited by 249
The Social Construction of the Human Brain
Eisenberg, L. (1995) · American Journal of Psychiatry · doi:10.1176/ajp.152.11.1563 · Cited by 249
Age-related macular degeneration (AMD): Alzheimer's disease in the eye?
Kaarniranta, K., Salminen, A., Haapasalo, A., Soininen, H., & Hiltunen, M. (2011) · Journal of Alzheimer s Disease · doi:10.3233/jad-2011-101908 · Cited by 248
“In contrast to AMD, the APOE-ε4 polymorphism represents the strongest thus far identified risk factor for AD, whereas the APOE- ε2 allele carriers have a reduced risk for developing AD (http://www.alzgene.org) [53] [54] [55] [56] [57].”
BackgroundMeta-Analysis of APOE 4 Allele and Outcome after Traumatic Brain Injury
Zhou, W., Xu, D., Peng, X., Zhang, Q., Jia, J., & Crutcher, K. A. (2008) · Journal of Neurotrauma · doi:10.1089/neu.2007.0489 · Cited by 244
“The apolipoprotein E4 allele (APOE4) has been established as a major genetic determinant of susceptibility to Alzheimer’s disease (Corder et al., 1993) that may act synergistically with a history of previous TBI (Mayeux et al., 1995).”
Apolipoprotein E genotyping in the differential diagnosis, not prediction, of Alzheimer's disease
Roses, A. D. (1995) · Annals of Neurology · doi:10.1002/ana.410380105 · Cited by 252
Self-citationBates, K. A., Verdile, G., Li, Q.-X., Ames, D., Hudson, P., Masters, C. L., & Martins, R. N. (2009) · Molecular Psychiatry · doi:10.1038/mp.2008.96 · Cited by 247
Ungar, L., Altmann, A., & Greicius, M. D. (2014) · Brain Imaging and Behavior · doi:10.1007/s11682-013-9272-x · Cited by 246
“The ε4 allele of the Apolipoprotein E gene (APOE4) is a potent genetic risk factor for sporadic and late-onset familial AD (Corder et al. 1993; Saunders et al. 1993; Strittmatter et al. 1993).”
InfluentialCoronary Artery Disease, Hypertension, ApoE, and Cholesterol: A Link to Alzheimer's Disease?
SPARKS, D. L. (1997) · Annals of the New York Academy of Sciences · doi:10.1111/j.1749-6632.1997.tb48466.x · Cited by 243
Tesseur, I., Van Dorpe, J., Spittaels, K., Van den Haute, C., Moechars, D., & Van Leuven, F. (2000) · The American Journal of Pathology · doi:10.1016/s0002-9440(10)64963-2 · Cited by 241
“2 (ApoE4) is associated with lateonset and sporadic Alzheimer’s disease (AD), as confirmed by many groups since the initial reports.(1,2) ApoE4 causes earlier onset of the disease in an allele-dosedependent manner and increases the risk for its carrier by 1 order of magnitude.”
BackgroundOffe, K., Dodson, S. E., Shoemaker, J. T., Fritz, J. J., Gearing, M., Levey, A. I., & Lah, J. J. (2006) · The Journal of Neuroscience · doi:10.1523/jneurosci.4946-05.2006 · Cited by 245
“Apolipoprotein E (ApoE) is the main lipoprotein expressed in the brain, and the APOE 4 allele is a major genetic risk factor for AD (Corder et al., 1993; Strittmatter et al., 1993).”
BackgroundGenetics of Alzheimer's Disease: A Centennial Review
Ertekin-Taner, N. (2007) · Neurologic Clinics · doi:10.1016/j.ncl.2007.03.009 · Cited by 234
“[93] demonstrated a dose-dependent increase in risk and a decrease in age-at-onset for LOAD, in ApoE ε4 carriers.”
BackgroundKatsel, P., Li, C., & Haroutunian, V. (2007) · Neurochemical Research · doi:10.1007/s11064-007-9297-x · Cited by 241
“[8, 9] and an significant component of lipid catabolism”
Grbovic, O. M., Mathews, P. M., Jiang, Y., Schmidt, S. D., Dinakar, R., Summers-Terio, N. B., Ceresa, B. P., Nixon, R. A., & Cataldo, A. M. (2003) · Journal of Biological Chemistry · doi:10.1074/jbc.m304122200 · Cited by 236
Calcium signaling in Alzheimer's disease & therapies
Tong, B. C.-K., Wu, A. J., Li, M., & Cheung, K.-H. (2018) · Biochimica et Biophysica Acta (BBA) - Molecular Cell Research · doi:10.1016/j.bbamcr.2018.07.018 · Cited by 231
Metadata
- Authors
- Corder, E. H., Saunders, A. M., Strittmatter, W. J., Schmechel, D. E., Gaskell, P. C., Small, G. W., Roses, A. D., Haines, J. L., & Pericak-Vance, M. A.
- Affiliations
- Duke University (US)
- Duke Medical Center (US)
- University of California, Los Angeles (US)
- Massachusetts General Hospital (US)
- Joseph and Kathleen Bryan Alzheimer's Disease Research Center, Duke University Medical Center, Durham, NC 27710.
- Venue
- Science
- Published
- 1993-08-13
- Volume
- 261
- Issue
- 5123
- Pages
- 921-923
- ISSN
- 0036-8075 (ISSN-L)
- 1095-9203
- OpenAlex
- W2036362108
- Cited by
- 9,429
- References
- 16
- Citations by year
- 2026: 289 · 2025: 380 · 2024: 355 · 2023: 328 · 2022: 356 · 2021: 378 · 2020: 396 · 2019: 358 · 2018: 341 · 2017: 343 · 2016: 345 · 2015: 303 · 2014: 343 · 2013: 335 · 2012: 333
- FWCI
- 135.93
- Type
- journal article
- Language
- en
- Open access
- closed
- Locations
- Science (publishedVersion)
- PubMed (publishedVersion)
- Topics
- Life Sciences › Neuroscience › Cellular and Molecular Neuroscience › Alzheimer's disease research and treatments
- Health Sciences › Medicine › Psychiatry and Mental health › Dementia and Cognitive Impairment Research
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Genetics › Genetic Associations and Epidemiology
- Keywords
- apolipoprotein E, APOE ε4, gene dosage, Alzheimer's disease, genetic risk, homozygosity, age of onset, genetic association
- MeSH terms
- Aged, Aged, 80 and over, Aging, Alleles, Alzheimer Disease, Apolipoproteins E, Female, Gene Frequency, Genotype, Homozygote, Humans, Male, Risk Factors, Linkage Disequilibrium, Survival Rate, Amyloid beta-Peptides, Apolipoprotein E4
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.